R&D The role of quality assurance in accelerating drug developme... The pharmaceutical landscape is experiencing a paradigm shift with the rise of gene therapies, cell therapies, and personalised medicine.
R&D IPF: Could we reverse the progression? Idiopathic Pulmonary Fibrosis (IPF) is a frightening, incurable disease where the lungs become increasingly damaged by scar tissue, resulting in breathing getting progressively more difficu
R&D How clinical research is zeroing in on fatty liver disease Americans’ livers are becoming increasingly unhealthy.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.